Methods for Identifying Microbial Natural Product Compounds that Target Kinetoplastid RNA Structural Motifs by Homology and De Novo Modeled 18S rRNA.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
26 Apr 2021
Historique:
received: 03 02 2021
revised: 22 02 2021
accepted: 24 02 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 20 5 2021
Statut: epublish

Résumé

The development of novel anti-infectives against Kinetoplastids pathogens targeting proteins is a big problem occasioned by the antigenic variation in these parasites. This is also a global concern due to the zoonosis of these parasites, as they infect both humans and animals. Therefore, we need not only to create novel antibiotics, but also to speed up the development pipeline for these antibiotics. This may be achieved by using novel drug targets for Kinetoplastids drug discovery. In this study, we focused our attention on motifs of rRNA molecules that have been created using homology modeling. The RNA is the most ambiguous biopolymer in the kinetoplatid, which carries many different functions. For instance, tRNAs, rRNAs, and mRNAs are essential for gene expression both in the pro-and eukaryotes. However, all these types of RNAs have sequences with unique 3D structures that are specific for kinetoplastids only and can be used to shut down essential biochemical processes in kinetoplastids only. All these features make RNA very potent targets for antibacterial drug development. Here, we combine in silico methods combined with both computational biology and structure prediction tools to address our hypothesis. In this study, we outline a systematic approach for identifying kinetoplastid rRNA-ligand interactions and, more specifically, techniques that can be used to identify small molecules that target particular RNA. The high-resolution optimized model structures of these kineoplastids were generated using RNA 123, where all the stereochemical conflicts were solved and energies minimized to attain the best biological qualities. The high-resolution optimized model's structures of these kinetoplastids were generated using RNA 123 where all the stereochemical conflicts were solved and energies minimized to attain the best biological qualities. These models were further analyzed to give their docking assessment reliability. Docking strategies, virtual screening, and fishing approaches successfully recognized novel and myriad macromolecular targets for the myxobacterial natural products with high binding affinities to exploit the unmet therapeutic needs. We demonstrate a sensible exploitation of virtual screening strategies to 18S rRNA using natural products interfaced with classical maximization of their efficacy in phamacognosy strategies that are well established. Integration of these virtual screening strategies in natural products chemistry and biochemistry research will spur the development of potential interventions to these tropical neglected diseases.

Identifiants

pubmed: 33925823
pii: ijms22094493
doi: 10.3390/ijms22094493
pmc: PMC8123475
pii:
doi:

Substances chimiques

Biological Products 0
Ligands 0
Protozoan Proteins 0
RNA, Ribosomal 0
RNA, Ribosomal, 18S 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Medicines for Malaria Venture
ID : PO 15/01083(02)

Références

Nucleic Acids Res. 2012 Aug;40(14):e112
pubmed: 22539264
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21
pubmed: 20057044
J Med Chem. 2004 Mar 25;47(7):1739-49
pubmed: 15027865
Trop Med Int Health. 2001 Nov;6(11):906-14
pubmed: 11703845
Front Microbiol. 2019 Oct 16;10:2375
pubmed: 31681232
Bioinformatics. 2009 Aug 1;25(15):1974-5
pubmed: 19398448
Expert Rev Anti Infect Ther. 2019 Jan;17(1):57-69
pubmed: 30513027
BMC Bioinformatics. 2002;3:2
pubmed: 11869452
Methods Mol Biol. 2016;1490:217-35
pubmed: 27665602
Methods Enzymol. 2009;458:59-91
pubmed: 19374979
Nucleic Acids Res. 1988 Nov 25;16(22):10881-90
pubmed: 2849754
J Am Chem Soc. 2019 May 1;141(17):6776-6790
pubmed: 30896935
Acta Trop. 2002 Feb;81(2):151-7
pubmed: 11801222
BMC Bioinformatics. 2010 Mar 15;11:129
pubmed: 20230624
J Clin Invest. 2008 Apr;118(4):1301-10
pubmed: 18382742
Nat Prod Rep. 2010 Sep;27(9):1276-95
pubmed: 20520915
J Biomol Struct Dyn. 2008 Jun;25(6):669-83
pubmed: 18399701
ACS Chem Biol. 2007 Nov 20;2(11):745-54
pubmed: 17975888
Nat Prod Rep. 2007 Dec;24(6):1245-61
pubmed: 18033578
Biotechnol Adv. 2020 Mar - Apr;39:107480
pubmed: 31707075
Nucleic Acids Res. 2016 Jan 4;44(D1):D7-19
pubmed: 26615191
Chemosphere. 2019 Nov;235:976-984
pubmed: 31561314
Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7799-7804
pubmed: 30926669
BMC Genomics. 2015 Oct 13;16:780
pubmed: 26463047
Nucleic Acids Res. 2018 Jul 2;46(W1):W30-W35
pubmed: 29718468
Curr Opin Drug Discov Devel. 2009 Mar;12(2):220-30
pubmed: 19333867
Biophys J. 2010 Mar 3;98(5):861-71
pubmed: 20197040
Nucleic Acids Res. 2007 Jan;35(Database issue):D301-3
pubmed: 17142228
Acta Pharm Sin B. 2017 Jan;7(1):97-105
pubmed: 28119814
J Cheminform. 2012 Aug 13;4(1):17
pubmed: 22889332
Neurotoxicology. 2018 May;66:195-203
pubmed: 29499217
Biomed Environ Sci. 1988 Jun;1(1):19-33
pubmed: 3151755
J Mol Biol. 1990 Oct 5;215(3):403-10
pubmed: 2231712
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147
Clin Microbiol Infect. 2018 Dec;24(12):1344.e1-1344.e4
pubmed: 29906591
Nat Commun. 2018 Feb 23;9(1):803
pubmed: 29476047

Auteurs

Harrison Ndung'u Mwangi (HN)

Department of Biochemistry, University of Nairobi, Nairobi 00200-30197, Kenya.

Edward Kirwa Muge (EK)

Department of Biochemistry, University of Nairobi, Nairobi 00200-30197, Kenya.

Peter Waiganjo Wagacha (PW)

Department of Computing and Informatics, University of Nairobi, Nairobi 00200-30197, Kenya.

Albert Ndakala (A)

Department of Chemistry, University of Nairobi, Nairobi 00200-30197, Kenya.

Francis Jackim Mulaa (FJ)

Department of Biochemistry, University of Nairobi, Nairobi 00200-30197, Kenya.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH